Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey (NHWS)
Abstract
Abstract
Introduction
The treatment landscape for the prevention of migraine has rapidly evolved in recent years with the advent of calcitonin gene-related peptide therapy, including erenumab. The objective of this study was to assess patient-reported treatment satisfaction among erenumab users.
Methods
This retrospective, cross-sectional study used data from the 2019 US National Health and Wellness Survey collected during March–July 2019. Respondents self-reporting physician-diagnosed migraine and currently using erenumab were analyzed. Treatment satisfaction was measured on a seven-point Likert scale. Data were further reported by the duration of erenumab treatment. Data on respondents’ socio-demographic characteristics and treatment patterns were also collected.
Results
Overall, 67 respondents using erenumab with or without other migraine preventives for up to 1 year were included in the analysis. The mean (standard deviation) age was 46.7 (12.9) years. Most of the respondents were women (86.6%), White (74.6%), and commercially-insured (67.2%). Notably, 40.3% had ≥1 comorbidity per the Charlson Comorbidity Index. Approximately half of the respondents were college graduates and employed (49.3% each). Among the 67 respondents, 46 received erenumab exclusively. Across both cohorts, the percentage of respondents who were satisfied with erenumab treatment was slightly higher among those with a longer treatment duration (overall erenumab cohort: 63.6%, 69.6%, and 75.8% for 0 to <3, 3 to <6, and 6 to 12 months, respectively; erenumab monotherapy cohort: 62.5%, 71.4%, and 87.5% for 0 to <3, 3 to <6, and 6 to 12 months, respectively). Treatment patterns before switching to erenumab revealed that most respondents had used ≥1 preventive treatment for migraine (80.6%; 54/67), over two-thirds (33/54) of whom had ≥2 treatment failures owing to nonresponse.
Conclusion
Satisfaction was high among long-term erenumab users, indicating that those using erenumab for a longer duration are more satisfied. Furthermore, this study provided insights on the basic socio-demographics, disease characteristics, and health behaviors of erenumab users as well as their treatment patterns before switching to erenumab.
Full text article
References
2. Rizzoli P, Mullally WJ: Headache. Am J Med. 2018, 131(1):17-24.
3. Agosti R: Migraine burden of disease: from the patient's experience to a socio-economic view. Headache. 2018, 58(S1):17-32.
4. Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S: Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018, 19(1):82.
5. Ong JJY, De Felice M: Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018, 15(2):274-290.
6. Bigal ME, Serrano D, Reed M, Lipton RB: Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurol. 2008, 71(8):559-566.
7. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al: Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013, 53(4):644-655.
8. Bonafede M, Wilson K, Xue F: Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 2019, 39(9):1086-1098.
9. Clark M, Schwedt TJ, Tepper SJ, Harris N, Martin S, Sapra S, et al: Patient satisfaction with prophylactic migraine medications. Headache. 2017, 57(Suppl 3):133.
10. Hepp Z, Bloudek LM, Varon SF: Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014, 20(1):22-33.
11. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al: Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017, 37(5):470-485.
12. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB: Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015, 35(6):478-488.
13. Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, et al: My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018, 19(1):115.
14. Woolley JM, Bonafede MM, Maiese BA, Lenz RA: Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017, 57(9):1399-1408.
15. Korolainen MA, Kurki S, Lassenius MI, Toppila I, Costa-Scharplatz M, Purmonen T, et al: Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain. 2019, 20(1):13.
16. Do TP, Guo S, Ashina M: Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019, 20(1):37.
17. Aimovig prescribing information [https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf]. Accessed 10 Dec 2020.
18. Barbanti P, Aurilia C, Egeo G, Fofi L: Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci. 2019, 40(Suppl 1):177-179.
19. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al: ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018, 38(6):1026-1037.
20. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al: A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377(22):2123-2132.
21. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP: A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020, 21(1):61.
22. Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020, 21(1):32.
23. Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al: Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020, 11: 417.
24. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018, 392(10161):2280-2287.
25. Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020, 21(1):69.
26. Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al: Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020, 21(1):84.
27. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017, 16(6):425-434.
28. American Headache Society: The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019, 59(1):1-18.
29. Leonard KV, Robertson C, Bhowmick A, Herbert LB: Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: A self-reported survey. Interact J Med Res. 2020, 9(1):e13029.
30. Fang J, Korrer S, Johnson J, Vo P, Cheadle A, Shah R, et al: Real-world trends in characteristics of migraine patients newly initiated on erenumab in the United States. Eur J Neurology. 2020, 27(Suppl 1):103-522.EPR1098.
31. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007, 68(5):343-349.
32. Faust E, Pivneva I, Betts KA, Ahmed Z, Joshi S, Hogan R, et al: Treatment patterns & baseline characteristics of patients with migraine treated with erenumab: Interim analysis of a multicenter chart-review study. Headache. 2019, 59(S1):200.
33. Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M: Erenumab prescription early view: Patient characteristics, treatment patterns, and adherence in the United States. Headache. 2019, 59(S1):199.
34. Bogdanov A, Chia V, Szekely C, Fischer L, Rasmussen S, Bensink ME, et al: Early use of erenumab in US real world practice. Headache. 2019, 59(S1):198.
35. Robbins L: CGRP monoclonal antibodies for chronic migraine. Pract Pain Manag. 2020, 19(6):58-62.